Sign up to save your podcasts
Or
Share Cast your vote! Nivolumab vs. Brentuximab for Classical Hodgkin Lymphoma
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Cast your vote! Nivolumab vs. Brentuximab for Classical Hodgkin Lymphoma
In this episode, Bernie and Anthony are joined by two special guest expert hematologists:
Dr. David Russler-Germain
Dr. Tycel Phillips
We discuss recent updates in the treatment of upfront Classical Hodgkin Lymphoma, including whether the SWOG S1826 and HD21 trials change practice! Will it be a landslide victory for nivolumab? Is brentuximab fired?
Stay tuned to find out!
View all episodes
By Bernard Marini, Anthony Perissinotti, et al.
4.5
2828 ratings
In this episode, Bernie and Anthony are joined by two special guest expert hematologists:
Dr. David Russler-Germain
Dr. Tycel Phillips
We discuss recent updates in the treatment of upfront Classical Hodgkin Lymphoma, including whether the SWOG S1826 and HD21 trials change practice! Will it be a landslide victory for nivolumab? Is brentuximab fired?
Stay tuned to find out!
More shows like WolverHeme Happy Hour
View all
JAMA Clinical Reviews
498 Listeners
The Hematologist
28 Listeners
OncoPharm
184 Listeners
The Peter Attia Drive
8,187 Listeners
VJHemOnc Podcast
2 Listeners
Plenary Session - inactive due to federal service
756 Listeners
Treating Blood Cancers
12 Listeners
Blood Podcast
53 Listeners
Oncology Today with Dr Neil Love
57 Listeners
Healthcare Unfiltered
136 Listeners
EHA Unplugged
1 Listeners
Blood Cancer Talks
49 Listeners
Two Onc Docs
185 Listeners
Oncology Brothers: Practice-Changing Cancer Discussions
43 Listeners
HemeTalks: Conversations in Hematology Education
3 Listeners